Use of Continuous Glucose Monitoring Indicators to Guide Dose Titration of Weekly Basal Insulin Efsitora Alfa in Insulin-Naive and Basal Insulin-Experienced Adults with Type 2 Diabetes: A Retrospective Analysis
Authors' conclusion
In insulin-naive and basal insulin-experienced populations treated with weekly efsitora, CGM indicators of hypoglycemia and fasting glucose yielded clinically equivalent dose titration decisions as CGM-derived hypoglycemic events and self-monitoring FPG, respectively.
Study context
- Population
- Insulin-naive and basal insulin-experienced adults with T2D treated with weekly insulin efsitora alfa
- Participants
- 466 vs 655
- Exposure
- Continuous glucose monitoring (CGM)-derived indicators vs self-monitoring fasting plasma glucose (FPG) and CGM-derived hypoglycemic events for weekly efsitora titration
- QWINT-2n = 466
- QWINT-3n = 655
- Outcome
- Agreement of CGM indicators with reference titration criteria
Methodological detailsdose-to-dose comparison, concordance analysis
- Dose-to-dose comparison
- Concordance analysis
Main finding
As reported in the abstract
CGM hypoglycemia indicators: agreement with CGM-derived hypoglycemic events in QWINT-2 and QWINT-3
91.5%-98.3%
CGM fasting indicators "Lowest median of ambulatory glucose profile (AGP)" and "Typical fasting 25% from AGP" clinically equivalent with FPG: dose decisions with dose differences within 20 weekly units, both studies
90.7%-93.4%
Observational data: associations, not effects.
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →